Skip to content

Evaluation on clinical efficacy of Modified Fuzheng Jiedu Huayu Decoction in the treatment of pneumonia caused by the drug - resistant Pseudomonas aeruginosa

Evaluation on clinical efficacy of Modified Fuzheng Jiedu Huayu Decoction in the treatment of pneumonia caused by the drug - resistant Pseudomonas aeruginosa

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087380
Enrollment
Unknown
Registered
2024-07-26
Start date
2023-05-21
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-resistant Pseudomonas aeruginosa pneumonia

Interventions

Experimental group:Standard medication&Jiawei Fuzheng Jiedu Huayu granules
Control group:Standard medication&placebo granules

Sponsors

Beijing University of Chinese Medicine Third Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (a)meet the diagnostic criteria of community-acquired pneumonia or hospital-acquired pneumonia, and etiology test meets the diagnostic criteria of drug-resistant Pseudomonas aeruginosa;(b)meet the TCM diagnostic criteria of wind-warm lung fever;(c)age = 18 years old;(d)patients or their legal guardians informed consent, and sign the informed consent.

Exclusion criteria

Exclusion criteria: (a) pregnant or lactating women; (b) patients with severe primary diseases such as heart, liver, kidney, hematopoietic system, late malignant tumor, poor blood glucose control of diabetes, and other basic diseases and mental patients that may affect the life cycle;(c) those who participated in or are participating in other clinical trials within 3 months; (d) those who are allergic to drugs used in this study.

Design outcomes

Primary

MeasureTime frame
Total efficiency;

Secondary

MeasureTime frame
28-day fatality rate;Sputum culture result;Complete Blood Count;CRP;PCT;IL-6;TNF-a;PSI score;CPIS score;Sequential Organ Failure Assessment, SOFA;antibiotic treatment;Main symptoms and signs;TCM syndrome elements;IgA;

Countries

China

Contacts

Public ContactWang Chengxiang

Beijing University of Chinese Medicine Third Affiliated Hospital

wang601@vip.sina.com+86 137 0139 5341

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026